Funding Search - Pivot

The University of Vermont, through Sponsored Project Administration (SPA) subscribes to Pivot, a web-based funding search tool. The UVM Cancer Center has collaborated with SPA to create a customized cancer relevant pivot search. Press the button for Cancer Funding Opportunities.

Cancer Funding Opportunities

 

If you would prefer to set up your own pivot search and automated alerts you can learn more about pivot HERE.


Limited Competition Funding

Limited Competitions (where the University may only submit a restricted number of applications) are managed though UVM's InfoReady Portal for Institutional Competitions. Go to https://uvm.infoready4.com/# to see all available competitions and enter “cancer” into the search box to see only cancer-specific opportunities.

You can also contact Edward North for information on applying for Limited Funding Opportunities. 

Peer-Reviewed Funding Sources

Below is a list of fund sources from federal agencies, non-profit foundations and regional and national organizations to support cancer research are provided below for UVM Cancer Center researchers. This of funding is considered NCI approved peer-reviewed funding and can also be found in PDF format at the following link: NCI Peer-Reviewed Fund Sources

  1. Agency for Healthcare Research and Quality (AHRQ)
  2. Alex’s Lemonade Stand Foundation (ALSF)
  3. American Association of Cancer Research (AACR)
  4. American Cancer Society (ACS) (national office only)
  5. American Foundation for AIDS Research (amfAR)
  6. American Institute for Cancer Research (AICR)
  7. California Institute for Regenerative Medicine (CIRM)
  8. Cancer Prevention Research Institute of Texas (CPRIT)
  9. Center for Disease Control and Prevention (CDC)
  10. Central Office of the Veterans Administration (VA) (excluding local/regional & “block” grants)
  11. Environmental Protection Agency (EPA)
  12. The Flight Attendant Medical Research Institute (FAMRI)
  13. Florida Biomedical Research Program (FBRP)
  14. Food and Drug Administration (FDA)
  15. Howard Hughes Medical Institute (HHMI)
  16. Leukemia and Lymphoma Society (LLS)
  17. Melanoma Research Alliance (MRA)
  18. Multiple Myeloma Research Foundation (MMRF)
  19. National Institute for Occupational Safety and Health (NIOSH)
  20. National Science Foundation (NSF)
  21. New York State Department of Health Wadsworth Center/New York State Stem Cell Science Program (NYSTEM)
  22. Patient-Centered Outcomes Research Institute (PCORI)
  23. Prevent Cancer Foundation (PCF)
  24. Prostate Cancer Foundation (PCF)
  25. Susan G. Komen for the Cure
  26. The California Breast Cancer Research Program (CBCRP)
  27. The California Tobacco Related Disease Research Program (TRDRP)
  28. U.S. Army (DOD) special research programs *

 

For Pivot Assistance

Please review the information provided by SPA

Hilda Alajajian, Grant Resources Specialist is available to meet with individuals or groups for assistance in identifying funding

Phone: (802)656-1322

Should you learn of an opportunity not listed here but important to UVM Cancer Center research, please contact Laura Gordon.

UVMCC Facilities & Resources Descriptions

“Boilerplate” descriptions of UVM Cancer Center-affiliated Resources & Facilities are provided at the links below. These are primarily intended for use in grant applications, including the “Facilities & Resources” section of NIH funding applications. Users are strongly urged to personalize the description to the greatest extent possible by adding details such as a history of collaboration resulting in publications and/or funded research awards.
University of Vermont Cancer Center (UVMCC)
Biobank
Cancer Translational Research Laboratory (CTRL)
Clinical Trials Office (CTO)
Microscopy Imaging Center (MIC)
Vermont Integrative Genomics Resource (VIGR)

 

Highlights: New & Updated

New and Updated
NCI- Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)

 

"Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies."

Deadline: June 09, 2021

Department of Defense Rare Cancers Research Program - Anticipated Funding Opportunities for Fiscal Year 2021 (FY21): Concept Award

Applications submitted to the FY21 RCRP must address one or more of the following Focus Areas:

 

  • Biology and Etiology: Identify disease-defining molecular pathways, cell context, and microenvironment.
  • Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness.
  • Therapy: Identify novel therapeutic strategies, including drug repurposing.

Investigators at or abovethe level of postdoctoral fellow

  • Supportsinnovative, high-risk/high-reward research that is in the earliest stages ofidea development or an untested theory that addresses an important problemrelated to rare cancers.  Proof-of-concept is the anticipated outcome.
  • Reviewerswill be blinded to the identity of the Principal Investigator, collaborators,and their organization(s).
  • Submissionmust address at least one of the FY21 Focus Areas of Biology and Etiology,Research Model, and/or Therapy.
  • Preliminarydata are not required.
  • Clinicaltrials are not allowed.
  • Maximumfunding of $100,000 for direct costs (plus indirect costs) 
  • Maximumperiod of performance is 1 year

https://cdmrp.army.mil/pubs/press/2021/21rcrppreann

 

A pre-application is required and must be submitted through theelectronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to thepre-application deadline. 

Submission deadlines are not available until the program announcementsare released.  For email notification when program announcements arereleased, subscribe to program-specific news and updates under “EmailSubscriptions” on the eBRAP homepage at https://eBRAP.org. 

Department of Defense Rare Cancers Research Program - Anticipated Funding Opportunities for Fiscal Year 2021 (FY21): Idea Development Award

Applications submitted to the FY21 RCRP must address one or more of the following Focus Areas:

 

  • Biology and Etiology: Identify disease-defining molecular pathways, cell context, and microenvironment.
  • Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness.
  • Therapy: Identify novel therapeutic strategies, including drug repurposing.

Investigatorsat or above the level of Assistant Professor

  • Preproposal submission is required; application submission is by invitation only.
  • Supports innovative, high-risk/high-reward research with the potential to yield impactful data in the rare cancer field.
  • Preliminary data with disease-specific rationale (including correlatives in existing trials) to support the feasibility of the research hypotheses and research approaches are required. 
  • Submissionmust address at least one of the FY21 Focus Areas of Biology and Etiology,Research Model, and/or Therapy.
  • Clinicaltrials are not allowed.
  • Maximumfunding of $350,000 for direct costs (plus indirect costs)  
  • Maximumperiod of performance is 3 years

 

https://cdmrp.army.mil/pubs/press/2021/21rcrppreann

 

A pre-application is required and must be submitted through theelectronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to thepre-application deadline. 

Submission deadlines are not available until the program announcementsare released.  For email notification when program announcements arereleased, subscribe to program-specific news and updates under “EmailSubscriptions” on the eBRAP homepage at https://eBRAP.org. 

 

Department of Defense Rare Cancers Research Program - Anticipated Funding Opportunities for Fiscal Year 2021 (FY21): Resource and Community Development Award

Applications submitted to the FY21 RCRP must address the FocusAreas below:

 

  • Platform Development: Development of platforms (such as tumor tissue repository with clinical annotation, centralized databanks, patient registry with common data structure, research model and Omics database, longitudinal studies of natural history, and treatment response) for multiple rare cancers, to allow sharing of data, bio-specimens, and resources.

Investigatorsat or above the level of Assistant Professor

  • Preproposal submission is required; application submission is by invitation only.
  • Emphasis on research resources development to facilitate collaboration and information sharing among stakeholders such as researchers, patients, family members, caregivers, clinicians, and other members of the rare cancers community. 
  • Supports platform development or infrastructure that can be applied to multiple rare cancers.
  • Preliminary data are not required but may be included (translational research and clinical studies may be included).
  • Submission must address the Platform Development Focus Area.
  • Clinical trials are not allowed.
  • Maximum funding of $600,000 for direct costs (plus indirect costs) 
  • Maximum period of performance is 3 years

 

https://cdmrp.army.mil/pubs/press/2021/21rcrppreann

 

A pre-application is required and must be submitted through theelectronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to thepre-application deadline. 

Submission deadlines are not available until the program announcementsare released.  For email notification when program announcements arereleased, subscribe to program-specific news and updates under “EmailSubscriptions” on the eBRAP homepage at https://eBRAP.org.